12 Month Price Forecast For ANVS
Distance to ANVS Price Forecasts
ANVS Price Momentum
๐ค Considering Annovis Bio (ANVS)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 11, 2025 3:27 AM UTC
ANVS Analyst Ratings & Price Targets
Based on our analysis of 8 Wall Street analysts, ANVS has a bullish consensus with a median price target of $26.00 (ranging from $21.00 to $72.00). Currently trading at $2.74, the median forecast implies a 848.9% upside. This outlook is supported by 5 Buy, 1 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Jason Kolbert at D. Boral Capital, suggesting a 666.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ANVS Analyst Consensus
ANVS Price Target Range
Latest ANVS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ANVS.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Feb 10, 2025 | D. Boral Capital | Jason Kolbert | Hold | Downgrade | $0.00 |
Nov 11, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $30.00 |
Nov 11, 2024 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $21.00 |
Oct 25, 2024 | Maxim Group | Jason McCarthy | Buy | Upgrade | $25.00 |
Oct 16, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $30.00 |
Oct 15, 2024 | EF Hutton | Jason Kolbert | Buy | Maintains | $21.00 |
Oct 1, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $30.00 |
Aug 15, 2024 | EF Hutton | Jason Kolbert | Buy | Maintains | $21.00 |
Aug 15, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $30.00 |
Aug 13, 2024 | EF Hutton | Jason Kolbert | Buy | Initiates | $21.00 |
Jul 17, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $30.00 |
Jul 11, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $30.00 |
Jul 2, 2024 | Rodman & Renshaw | Elemer Piros | Buy | Reiterates | $67.00 |
Jun 12, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $23.00 |
Jun 4, 2024 | Rodman & Renshaw | Buy | Initiates | $67.00 | |
May 13, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $23.00 |
Apr 30, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $30.00 |
Apr 30, 2024 | Canaccord Genuity | Sumant Kulkarni | Buy | Maintains | $26.00 |
Apr 2, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $30.00 |
Mar 21, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $30.00 |
Stocks Similar to Annovis Bio Inc
The following stocks are similar to Annovis Bio based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Annovis Bio Inc (ANVS) Financial Data
Annovis Bio Inc has a market capitalization of $53.59M with a P/E ratio of -0.4x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -596.7%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

Annovis Bio Inc (ANVS) Company Overview
About Annovis Bio Inc
Develops drugs for neurodegenerative diseases.
Annovis Bio, Inc. operates as a clinical stage drug platform company, focusing on the development of innovative therapies for neurodegeneration. The company generates value through the advancement of its drug candidates, primarily Buntanetap, ANVS405, and ANVS301, which are aimed at treating conditions like Alzheimer's and Parkinson's disease. Revenue will be generated through potential future sales of these drugs upon successful clinical trials and subsequent market approval.
Incorporated in 2008 and headquartered in Malvern, Pennsylvania, Annovis Bio has completed significant clinical trials and is actively pursuing multiple drug candidates in various stages of development. Their focus on neurodegenerative diseases addresses a critical area of unmet medical need, potentially positioning them for lucrative partnerships or acquisitions in the pharmaceutical industry.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
6
CEO
Dr. Maria L. Maccecchini Ph.D.
Country
United States
IPO Year
2020
Website
www.annovisbio.comAnnovis Bio Inc (ANVS) Latest News & Analysis
Annovis Bio Inc. (NYSE: ANVS) has initiated a pivotal Phase 3 study for its drug buntanetap in early Alzheimer's disease, with the first two patients enrolled.
The initiation of a pivotal Phase 3 study for buntanetap in early Alzheimer's could lead to significant advancements in treatment, impacting Annovis Bio's market potential and stock performance.
Annovis Bio Inc. (NYSE: ANVS) announced CEO Maria Maccecchini will present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference, focusing on therapies for Alzheimer's and Parkinson's diseases.
Annovis Bio's CEO presenting at a major healthcare conference highlights the company's visibility and potential growth in the neurodegenerative disease market, crucial for investor sentiment and stock performance.
Annovis Bio, Inc. announced a public offering of 5.25 million shares and warrants at $4.00 each, aiming for $21 million in gross proceeds. The offering closes on February 4, 2025.
Annovis Bio's public offering indicates financial strategy and potential growth, raising $21M for R&D in neurodegenerative diseases, which could impact stock performance and investor confidence.
Annovis Bio, Inc. closed a public offering of 5.25 million shares and warrants at $4.00 each, raising $21 million. Warrants are exercisable at $5.00 for five years.
Annovis Bio's $21 million raise through a public offering signals confidence in its pipeline for neurodegenerative disease therapies, potentially impacting stock value and investor interest.
Annovis Bio, Inc. plans to launch an underwritten public offering of common stock and warrants, with all shares sold by the company.
Annovis Bio's stock offering may dilute existing shares, impacting current shareholders' value. It signals the company's need for capital, influencing investor sentiment and stock price.
Annovis Bio Inc. (NYSE: ANVS) announced it received a U.S. patent for using buntanetap to treat and prevent acute brain or nerve injuries, enhancing its portfolio in neurodegenerative therapies.
The patent grants Annovis Bio exclusive rights to a potentially groundbreaking treatment for brain injuries, which could enhance its market position and drive stock value.
Frequently Asked Questions About ANVS Stock
What is Annovis Bio Inc's (ANVS) stock forecast for 2025?
Based on our analysis of 8 Wall Street analysts, Annovis Bio Inc (ANVS) has a median price target of $26.00. The highest price target is $72.00 and the lowest is $21.00.
Is ANVS stock a good investment in 2025?
According to current analyst ratings, ANVS has 5 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.74. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for ANVS stock?
Wall Street analysts predict ANVS stock could reach $26.00 in the next 12 months. This represents a 848.9% increase from the current price of $2.74. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Annovis Bio Inc's business model?
Annovis Bio, Inc. operates as a clinical stage drug platform company, focusing on the development of innovative therapies for neurodegeneration. The company generates value through the advancement of its drug candidates, primarily Buntanetap, ANVS405, and ANVS301, which are aimed at treating conditions like Alzheimer's and Parkinson's disease. Revenue will be generated through potential future sales of these drugs upon successful clinical trials and subsequent market approval.
What is the highest forecasted price for ANVS Annovis Bio Inc?
The highest price target for ANVS is $72.00 from at , which represents a 2,527.7% increase from the current price of $2.74.
What is the lowest forecasted price for ANVS Annovis Bio Inc?
The lowest price target for ANVS is $21.00 from Jason Kolbert at D. Boral Capital, which represents a 666.4% increase from the current price of $2.74.
What is the overall ANVS consensus from analysts for Annovis Bio Inc?
The overall analyst consensus for ANVS is bullish. Out of 8 Wall Street analysts, 5 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $26.00.
How accurate are ANVS stock price projections?
Stock price projections, including those for Annovis Bio Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.